ADRX catalysts
Catalysts and events linked to ADRX, newest first.
ADRX stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| ADARx Pharmaceuticals Prices Upsized $446.3M IPO at $17 per Share 2026-09-25 · Watch | primary equity issuance establishing initial trading valuation | ADARx priced 26.25M shares at $17 per share to raise $446.3M gross. | Not recorded |
| ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq 2026-09-25 · Up | initial market trading liquidity following upsized primary offering | Priced 26.25M shares at $17.00, raising $446.3M in gross proceeds. | Not recorded |
| ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share 2026-09-25 · Up | debut secondary market liquidity and balance sheet capitalization | Trading begins on Nasdaq on September 25, 2026 under ticker ADRX. | Not recorded |
| ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17 2026-09-25 · Up | nasdaq public listing and capital raise liquidity | Priced upsized IPO at $17/share generating $446.3M gross proceeds. | Not recorded |
| ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share 2026-09-25 · Watch | primary market pricing and Nasdaq debut trading | ADARx priced 26.25M shares at $17.00 to raise $446.3M gross proceeds. | Not recorded |
| ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share 2026-09-25 · Watch | initial market trading valuation and secondary liquidity formation | Priced 26.25M shares at $17 to raise $446.3M ahead of Nasdaq debut | Not recorded |
| ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17 2026-09-25 · Up | first-day trading liquidity and IPO capitalization | Priced 26.25M shares at $17/share to raise $446.3M gross proceeds. | Not recorded |
| ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17 2026-09-25 · Up | nasdaq public listing price discovery and liquidity injection | ADARx Pharmaceuticals priced its upsized IPO at $17 per share for $446.3M gross proceeds. | Not recorded |
Do these developments change your position?
Review ADRX alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-25ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per shareADRX-5.68%
- 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqADRX XBI-3.04%
- 2026-09-25ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per shareADRX-5.68%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17ADRX XBI-3.04%
- 2026-09-25ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per shareADRX-5.68%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17ADRX-5.68%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M IPO at $17 per ShareADRX-5.68%
- 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqADRX XBI-3.04%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per ShareADRX XBI-3.04%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17ADRX-5.68%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/ShareADRX-5.68%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.